Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T70888
|
||||
| Target Name |
TNF receptor
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Asthma [ICD10: J45] | ||||
| Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26] | |||||
| Inflammatory disorder [ICD code not available] | |||||
| Pemphigus vulgaris; Vasculitis; Wegener's granulomatosis [ICD10: C91-C95, J45, J84.1, L80, M081, M45, M35.0, M40-M54, T86.0] | |||||
| Sciatica [ICD10: M54.3-M54.4] | |||||
| BioChemical Class |
Tumor necrosis factor receptor superfamily (TNFRSF)
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Etanercept | Drug Info | Approved | Active rheumatoid arthritis | [1] |
| Etanercept | Drug Info | Phase 3 | Sciatica | [2], [3] | |
| Etanercept | Drug Info | Phase 2 | Pemphigus vulgaris; Vasculitis; Wegener's granulomatosis | [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21] | |
| TgAAV-TNFR:Fc | Drug Info | Phase 1/2 | Inflammatory disorder | [22] | |
| Lenercept | Drug Info | Discontinued in Phase 3 | Asthma | [23] | |
| BB-2275 | Drug Info | Terminated | Human immunodeficiency virus infection | [24] | |
| Modulator | BB-2275 | Drug Info | |||
| Etanercept | Drug Info | [2] | |||
| Lenercept | Drug Info | ||||
| TgAAV-TNFR:Fc | Drug Info | ||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| REF 2 | Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1-4. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6789). | ||||
| REF 4 | ClinicalTrials.gov (NCT00001901) Etanercept to Treat Wegener's Granulomatosis | ||||
| REF 5 | ClinicalTrials.gov (NCT00001954) Etanercept Therapy for Sjogren's Syndrome | ||||
| REF 6 | ClinicalTrials.gov (NCT00005007) Etanercept for Wegener's Granulomatosis | ||||
| REF 7 | ClinicalTrials.gov (NCT00006070) Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction | ||||
| REF 8 | ClinicalTrials.gov (NCT00034060) The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept | ||||
| REF 9 | ClinicalTrials.gov (NCT00063869) Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis | ||||
| REF 10 | ClinicalTrials.gov (NCT00107991) Etanercept for Treatment of Hidradenitis | ||||
| REF 11 | ClinicalTrials.gov (NCT00134368) Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo | ||||
| REF 12 | ClinicalTrials.gov (NCT00135720) Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | ||||
| REF 13 | ClinicalTrials.gov (NCT00141713) The Use of Etanercept (Enbrel) in the Treatment of Acute Graft-Versus-Host Disease | ||||
| REF 14 | ClinicalTrials.gov (NCT00141726) Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant | ||||
| REF 15 | ClinicalTrials.gov (NCT00141739) Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) | ||||
| REF 16 | ClinicalTrials.gov (NCT00141791) Study Evaluating Etanercept in Moderate to Severe Asthma | ||||
| REF 17 | ClinicalTrials.gov (NCT00509600) Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | ||||
| REF 18 | ClinicalTrials.gov (NCT01289730) Etanercept (Enbrel) in Undifferentiated Spondyloarthritis | ||||
| REF 19 | ClinicalTrials.gov (NCT01289743) Etanercept (Enbrel) in Ankylosing Spondylitis | ||||
| REF 20 | ClinicalTrials.gov (NCT01730495) Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome | ||||
| REF 21 | ClinicalTrials.gov (NCT02656082) Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus | ||||
| REF 22 | Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. | ||||
| REF 23 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004745) | ||||
| REF 24 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003251) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.